Opendata, web and dolomites

OSTEOproSPINE SIGNED

Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OSTEOproSPINE project word cloud

Explore the words cloud of the OSTEOproSPINE project. It provides you a very rough idea of what is the project "OSTEOproSPINE" about.

grant    profile    degenerative    ethics    regeneration    crest    trial    conditional    autograft    molecular    permissive    conduct    fp7    positive    279239    osteogrow    microenvironment    blinded    granted    chronic    generating    pain    standard    autologous    vienna    care    bone    suffering    humans    supporting    coagulum    fusion    fracture    form    cells    recombinant    skeletal    health    morphogenetic    osteoprospine    blood    treatment    rate    matrix    vertebrae    life    signals    radius    reduce    patient    delivered    ground    enroll    surgery    intractable    centers    13    protein    approval    outcome    trials    efficacy    back    site    osteotomy    regenerative    extra    excellent    administration    presumptive    medicine    population    lumbar    exhibited    assembled    function    replace    spinal    committee    functioning    human    patients    bearing    posterolateral    guide    distal    reinforced    disc    rhbmp6    clinical    weight    safety    compression    confirm    iliac    spine    disorders    tibial    peripheral    resistant    180    correct    designed    quality    severity    disease    randomized    therapy    harvested    evaluation    evaluator    restore    allograft   

Project "OSTEOproSPINE" data sheet

The following table provides information about the project.

Coordinator
SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET 

Organization address
address: SALATA 3
city: ZAGREB
postcode: 10 000
website: www.mef.unizg.hr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Croatia [HR]
 Total cost 6˙004˙152 €
 EC max contribution 6˙004˙152 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET HR (ZAGREB) coordinator 710˙750.00
2    GENERA ISTRAZIVANJA DRUSTVO S OGRANICENOM ODGOVORNOSCU ZA PROIZVODNJU BIOTEHNOLOSKIH PROIZVODA HR (KALINOVICA) participant 1˙138˙750.00
3    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 848˙625.00
4    CLINRES FARMACIJA RAZISKAVE DOO SI (LJUBLJANA) participant 705˙762.00
5    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 454˙375.00
6    UNIVERSITAT LINZ AT (LINZ) participant 423˙750.00
7    2KMM SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA PL (KATOWICE) participant 377˙250.00
8    MEDIZINISCHE UNIVERSITAT GRAZ AT (GRAZ) participant 347˙500.00
9    QBEX GMBH AT (KLAGENFURT) participant 295˙346.00
10    SMART-MEDICO DOO HR (ZAGREB) participant 253˙532.00
11    UNIVERSITY OF ZAGREB-FACULTY OF VETERINARY MEDICINE HR (ZAGREB) participant 251˙250.00
12    TRIADELTA PARTNERI DOO ZA ISTRAZIVANJE I RAZVOJ HR (ZAGREB GRAD ZAGREB) participant 183˙107.00
13    PAUL REGULATORY SERVICES LIMITED UK (CARDIFF) participant 14˙154.00
14    OPCA BOLNICA VARAZDIN HR (VARAZDIN) participant 0.00

Map

 Project objective

We propose a clinical program for the evaluation of a novel bone-regeneration product OSTEOproSPINE as a treatment for intractable chronic back pain. OSTEOproSPINE is a novel bone regeneration therapy composed of OSTEOGROW (recombinant human bone morphogenetic protein 6 [rhBMP6] delivered in autologous peripheral blood coagulum) reinforced with allograft (a compression resistant matrix). OSTEOproSPINE is designed to guide the formation of new bone at extra-skeletal site and replace autograft harvested from patient’s iliac crest for the fusion of lumbar vertebrae. By generating new bone, OSTEOproSPINE will restore the spine’s weight bearing function, reduce the severity of back pain and improve the success rate of posterolateral spinal fusion surgery. The program consortium of 13 partners from 6 EU member states has been assembled to conduct a Phase II, randomized, patient- and evaluator-blinded clinical trial of OSTEOproSPINE. Four clinical centers will enroll 180 patients suffering from degenerative disc disease to assess OSTEOproSPINE efficacy and safety in comparison with Standard of care (autograft) and Osteogrow. The Ethics Committee of the leading clinical site in Vienna has already granted a conditional approval for this trial. As the coordinating institution of the FP7 HEALTH project Osteogrow (Grant No. 279239), we have evaluated Osteogrow in Phase I/II clinical trials for distal radius fracture and high tibial osteotomy. Osteogrow exhibited excellent safety profile in these trials, supporting OSTEOproSPINE safety for administration in humans. A positive outcome of proposed trial will confirm OSTEOproSPINE potential to form a functioning new bone in human and by this restore the spine’s function and improve the quality of life in patients with degenerative disc disorders using the ground principle of regenerative medicine: “provide the correct molecular signals to a population of presumptive cells in a permissive microenvironment”.

 Deliverables

List of deliverables.
Data Management Plan Open Research Data Pilot 2019-10-03 18:11:11
Public project website Websites, patent fillings, videos etc. 2019-10-03 18:11:11

Take a look to the deliverables list in detail:  detailed list of OSTEOproSPINE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OSTEOPROSPINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OSTEOPROSPINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More